Progression-free survival increased with zanubrutinib in leukemia

by Elana Gotkine HealthDay ReporterProgression-free survival is significantly longer with zanubrutinib than ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or s

Updated on: December 19,2023

Progression-free survival increased with zanubrutinib in leukemia

by Elana Gotkine HealthDay ReporterProgression-free survival is significantly longer with zanubrutinib than ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or s

Updated on:December 19,2023

Splicing deregulation detected and targeted in type of childhood leukemia

byUniversity of California - San DiegoA micrograph depicts acute myeloid leukemia cells. Though treatments have dramatically advanced, AML in children can become resistant to therapy. New resear

Updated on: December 21,2023

Splicing deregulation detected and targeted in type of childhood leukemia

byUniversity of California - San DiegoA micrograph depicts acute myeloid leukemia cells. Though treatments have dramatically advanced, AML in children can become resistant to therapy. New resear

Updated on:December 21,2023

FDA approval of 4-drug combination for front-line treatment of metastatic pancreatic cancer

by Denise Heady,University of California, Los AngelesKaplan–Meier estimates of overall survival (A) and progression-free survival (B) NALIRIFOX=liposomal irinotecan in combination with fluoroura

Updated on: March 22,2024

FDA approval of 4-drug combination for front-line treatment of metastatic pancreatic cancer

by Denise Heady,University of California, Los AngelesKaplan–Meier estimates of overall survival (A) and progression-free survival (B) NALIRIFOX=liposomal irinotecan in combination with fluoroura

Updated on:March 22,2024

Scientists unveil chemotherapy resistance mechanism related to p53 mutation

by Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem (INBEB)Comparison between the response of tumoral cells to chemotherapy with no mutation of p53 (upper cells) and of mu

Updated on: December 20,2023

Scientists unveil chemotherapy resistance mechanism related to p53 mutation

by Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem (INBEB)Comparison between the response of tumoral cells to chemotherapy with no mutation of p53 (upper cells) and of mu

Updated on:December 20,2023

Study ties diabetes and obesity to increased risk of liver cancer relapse

byOsaka Metropolitan UniversityDiabetes mellitus and obesity are risks for late postoperative recurrence of hepatocellular carcinoma. Credit: Osaka Metropolitan UniversityHepatocellular carcinom

Updated on: October 24,2024

Study ties diabetes and obesity to increased risk of liver cancer relapse

byOsaka Metropolitan UniversityDiabetes mellitus and obesity are risks for late postoperative recurrence of hepatocellular carcinoma. Credit: Osaka Metropolitan UniversityHepatocellular carcinom

Updated on:October 24,2024

New study using novel approach for glioblastoma treatment shows promising results, extending survival

byUniversity Health NetworkAn illustration of oncolytic virus and an anti-PD-1 antibody working together to defeat cancer cells. Credit: Tal BavliA new international study published inNatu

Updated on: January 04,2024

New study using novel approach for glioblastoma treatment shows promising results, extending survival

byUniversity Health NetworkAn illustration of oncolytic virus and an anti-PD-1 antibody working together to defeat cancer cells. Credit: Tal BavliA new international study published inNatu

Updated on:January 04,2024

New epigenetic markers for prostate cancer discovered

byGarvan Institute of Medical ResearchHistopathological image of a high grade prostate cancer. Credit: Prof James KenchNew epigenetic biomarkers to predict more aggressive forms of prostate canc

Updated on: December 21,2023

New epigenetic markers for prostate cancer discovered

byGarvan Institute of Medical ResearchHistopathological image of a high grade prostate cancer. Credit: Prof James KenchNew epigenetic biomarkers to predict more aggressive forms of prostate canc

Updated on:December 21,2023

Out-of-pocket costs for cancer care keep climbing

Cancerpatients already have a lot to deal with emotionally and physically. But research shows that insured patients under 65 are also paying more for their treatments out-of-pocket than ever bef

Updated on: December 18,2023

Out-of-pocket costs for cancer care keep climbing

Cancerpatients already have a lot to deal with emotionally and physically. But research shows that insured patients under 65 are also paying more for their treatments out-of-pocket than ever bef

Updated on:December 18,2023

CHMP Recommends Against Renewal of Marketing Authorization for Belantamab Mafodotin in R/R Myeloma

September 18, 2023Chris RyanThe European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended against renewal of the conditional marketing authorization for belantamab maf

Updated on: October 24,2023

CHMP Recommends Against Renewal of Marketing Authorization for Belantamab Mafodotin in R/R Myeloma

September 18, 2023Chris RyanThe European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended against renewal of the conditional marketing authorization for belantamab maf

Updated on:October 24,2023

Is AI Ready to Play a Leading Role in Colorectal Cancer Screening?

by Sharon ReynoldsArtificial intelligence, or AI, is suddenly everywhere. From ChatGPT to automated customer service "representatives,” the ability of computers to perform increasingly complicate

Updated on: October 15,2023

Is AI Ready to Play a Leading Role in Colorectal Cancer Screening?

by Sharon ReynoldsArtificial intelligence, or AI, is suddenly everywhere. From ChatGPT to automated customer service "representatives,” the ability of computers to perform increasingly complicate

Updated on:October 15,2023

Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

September 20, 2021Kristie L. KahlFirst-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.First-line sunitinib (Sut

Updated on: October 24,2023

Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

September 20, 2021Kristie L. KahlFirst-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.First-line sunitinib (Sut

Updated on:October 24,2023

Maveropepimut-S Plus Pembrolizumab and Cyclophosphamide Shows Early Promise in R/R DLBCL

February 13, 2023Kristi RosaThe combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cel

Updated on: October 17,2023

Maveropepimut-S Plus Pembrolizumab and Cyclophosphamide Shows Early Promise in R/R DLBCL

February 13, 2023Kristi RosaThe combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cel

Updated on:October 17,2023